Motion sickness drug linked to cases of robbery and assault – here's what you need to know about ‘devil's breath'
While most reports of devil's breath come from countries like Colombia, concerns about its use in Europe are not new. In 2015, three people were arrested in Paris for allegedly using the drug to rob victims, turning them into compliant 'zombies'.
The UK's first known murder linked to scopolamine was reported in 2019 when the Irish dancer Adrian Murphy was poisoned by thieves attempting to sell items stolen from him. In a more recent case in London, a woman reported symptoms consistent with scopolamine exposure after being targeted on public transport.
Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences.
Scopolamine, also known as hycosine, is a tropane alkaloid, a type of plant-derived compound found in the nightshade family (Solanaceae). It has a long history: indigenous communities in South America traditionally used it for spiritual rituals due to its potent psychoactive effects.
In modern medicine, scopolamine (marketed in the UK as hyoscine hydrobromide) is prescribed to prevent motion sickness, nausea, vomiting and muscle spasms. It also reduces saliva production before surgery. Brand names include Kwells (tablets) and Scopoderm (patches).
As an anticholinergic drug, scopolamine blocks the neurotransmitter acetylcholine, which plays a vital role in memory, learning, and coordination. Blocking it helps reduce nausea by interrupting signals from the balance (vestibular) system to the brain. But it also comes with side effects, especially when used in high doses or outside a clinical setting.
Scopolamine disrupts the cholinergic system, which is central to memory formation and retrieval. As a result, it can cause temporary but severe memory loss: a key reason it's been weaponised in crimes. Some studies also suggest it increases oxidative stress in the brain, compounding its effects on cognition.
The drug's power to erase memory, sometimes described as 'zombifying', has made it a focus of forensic and criminal interest. Victims often describe confusion, hallucinations and a complete loss of control.
In clinical settings, scopolamine is sometimes used off-label for depression, excessive sweating, or even to help quit smoking. But outside these uses, it's increasingly associated with danger.
Recreational users are drawn to its hallucinogenic effects – but the line between tripping and toxic is razor thin.
In Colombia and other parts of South America, scopolamine, also known as burundanga, has been implicated in countless robberies and sexual assaults. Victims describe feeling dreamlike, compliant, and unable to resist or recall events. That's what makes it so sinister – it robs people of both agency and memory.
The drug is often administered surreptitiously. In its powdered form, it's odourless and tasteless, making it easy to slip into drinks or blow into someone's face, as some victims have reported. Online forums detail how to make teas or infusions from plant parts, seeds, roots, flowers – heightening the risk of DIY misuse.
Once ingested, the drug works quickly and exits the body within about 12 hours, making it hard to detect in routine drug screenings. For some people, even a dose under 10mg can be fatal.
Signs of scopolamine poisoning include rapid heartbeat and palpitations, dry mouth and flushed skin, blurred vision, confusion and disorientation, hallucinations and drowsiness.
If you experience any of these, especially after an unexpected drink or interaction, seek medical attention immediately.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Dipa Kamdar does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
Help! My Patient Asked Me About Their Smartwatch HRV Status!
In recent years, smartwatches have gained popularity across Europe, driven by an increase in health awareness, smartphone integration, and advancements in wearable technology. They are now able to monitor an increasing number of health metrics, including the now-popular heart rate variability (HRV). So what happens when a patient comes to the clinic worried about their HRV status, as reported by their watch? To learn more about HRV and its clinical significance, Medscape Medical News spoke with two experts. Professor Thomas Gronwald, PhD, is head of the Department of Performance, Neuroscience, Therapy and Health at MSH Medical School Hamburg, Germany. He is an exercise and training scientist with a focus on internal and external load analysis in strength and conditioning training. Cailbhe Doherty, PhD, is an assistant professor at the School of Public Health, Physiotherapy, and Sports Science at University College Dublin, Ireland. His research is dedicated to investigating the effectiveness of consumer wearables in public health and the integration of mobile technologies in healthcare systems. What is HRV? And is it possible for smartwatches/wearables to accurately measure it? Thomas Gronwald, PhD Doherty: HRV is the variation in time between successive heartbeats. So even if your heart is beating at 60 beats/min, that doesn't mean it's beating exactly once every second. There are tiny fluctuations between beats — sometimes 0.98 seconds, sometimes 1.02 — and that variation is what we call HRV. Those fluctuations aren't random. They're governed by your autonomic nervous system…and within that system, there's a kind of balance: the sympathetic branch, which speeds things up (fight or flight), and the parasympathetic branch, which slows things down (rest and digest). HRV reflects that balance. In simple terms, a higher HRV generally indicates a more adaptable, resilient nervous system, and it's often used as a proxy for recovery, stress, and overall cardiovascular health. Gronwald: The gold standard for a valid and reliable assessment of the time between two successive heartbeats is the electrocardiogram (ECG), which allows recordings in the laboratory or during daily activity — up to 24 hours or longer. Several mobile and user-friendly measurement systems and wearables exist, which can record R-R intervals with different applications and form factors — chest strap systems, adhesive patches, and electrode systems on the skin — that utilize not only electrophysiologic but also optically derived signals such as photoplethysmography…. Most commercially available portable devices show a low absolute error under resting conditions but should always be validated against reference measures to clarify the accuracy of data parameters and maximize real-world application value. Is HRV an important measure of someone's health? Is it an important measure for an athlete? Doherty: Yes, but with some important qualifications. HRV can be a valuable indicator of health, but it's not a silver bullet. In a general health context, higher HRV is often associated with better cardiovascular health, lower levels of chronic stress, and even reduced risk for mortality…. It's a useful window into your overall resilience. The issue is that HRV is highly individual. What's high for one person might be low for another. It's not the kind of measure where a single value tells the whole story. You really need to look at trends over time and ideally interpret them in the context of things like sleep, recovery, illness, and training load. Gronwald: The usefulness of HRV as an indicator of physiologic and pathologic conditions, for risk stratification, and as a marker of autonomic adaptive and regulatory capacity is evident. However, longitudinal data recordings are recommended when trend analysis with contextual data is intended. Considering the mentioned context-sensitive requirements, HRV analysis allows for longitudinal trend analysis of patients and healthy individuals, including athletic and nonathletic populations in various clinical and performance-related settings. This includes the application of HRV monitoring for resting conditions, during and/or after biofeedback and training interventions, as well as general relationships between recovery status, previous exercise conditions, and symptoms of overreaching and overtraining. What should a doctor do if someone goes to them saying their smartwatch is showing that they continuously have a low HRV status? Cailbhe Doherty, PhD Doherty: I'd suggest it should be treated as a starting point. The physician might ask: Has this person noticed other symptoms — fatigue, poor sleep, high stress? Has their resting heart rate changed? Are there lifestyle factors — alcohol, illness, overtraining, or mental health — that could explain the trend? And if it seems warranted, they could conduct more standardized assessments, such as an ECG-based HRV measurement or a broader autonomic function test. The data is not medical grade and we don't know enough about how the proprietary algorithms are processing the signals. But if the question is whether the HRV trend might reflect something real, then yes, it's possible. Ultimately, I think wearables are better at raising questions than answering them. And that's not a bad thing. Is such data reliable? Gronwald: This depends strongly on the wearable or recording device. The measurement principles and the type of analysis and processing of the biosignal vary significantly between different devices. On the one hand, sleep analyses are used during the night, while on the other hand, context-free time points during the day are often used. Here, care should be taken to include standardized situations for a measurement and interpretation context. It is recommended to use validated measurement systems that either use the entire night as a reference phase or a consistent measurement situation early in the morning after waking up without prior stressors. Both approaches have advantages and disadvantages. How can someone improve their HRV? Gronwald: HRV improves when the body is balanced between activity and recovery within hemodynamic boundaries, with strong support from sleep, stress reduction, and a healthy active lifestyle. Regular physical activity, especially moderate aerobic exercise — such as walking, cycling, or swimming — and strength training can increase HRV over time. Breathing exercises with slow, deep, and diaphragmatic breathing — for example 4-6 breaths per minute — can help to activate the parasympathetic nervous system, which improves HRV. Good sleep quality with consistent sleep patterns, enough deep sleep, and avoiding late-night screen time and activity are essential for higher HRV. Further, stress management and practices such as meditation, social connection, mindfulness, or progressive muscle relaxation are linked to emotional well-being and can reduce stress and therefore improve HRV. Finally, healthy nutrition habits such as a balanced diet rich in whole foods, omega-3 fatty acids, fruits, and vegetables supports HRV — including limitation of stimulants, alcohol, nicotine, and processed foods. How important do you think wearable technology is to support the provision of healthcare across Europe? What role do you think it will play in the future? Doherty: Healthcare systems across Europe are facing enormous pressure: aging populations, rising chronic disease, long waiting lists, and constrained resources. Wearables offer something really compelling in that context: the ability to monitor people continuously, passively, and remotely, outside the clinic, in real-world settings. [But] at the moment, most wearable data isn't integrated into the healthcare system. It lives in consumer ecosystems — Apple, Google, Fitbit, Garmin — and that creates problems around standardization, privacy, and clinical utility. We can't expect a GP or a cardiologist to wade through raw data from 10 different apps and figure out what it means. There are also big equity issues. Most wearables are still designed and validated in relatively narrow populations — usually younger, healthier, often White, middle-income users. If we start using wearable data in clinical decision-making, we need to be absolutely sure it's valid across diverse populations, otherwise we risk baking health inequalities into digital health systems. Another issue is data privacy. When we start linking consumer data to clinical records, the stakes get much higher. Who owns the data? Who profits from it? Who gets access to it? Ultimately, I think wearables will play an increasingly important role in population health monitoring, early detection, and personalized prevention. But for that to happen in a way that is safe, effective, and fair, we need interoperability, regulatory oversight — especially on algorithm transparency, robust validation in real-world populations, and a clear framework around data rights and governance. Gronwald and Doherty reported no relevant financial relationships.
Yahoo
3 hours ago
- Yahoo
Pfizer battles another Paxlovid lawsuit from Enanta
If you don't succeed at first, try again – in separate regions. That's the motto Enanta Pharmaceuticals is following, at least, after disclosing it has sued Pfizer in Europe over a patent infringement relating to Covid-19 treatment pill Paxlovid (nirmatrelvir/ritonavir). In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma company infringed on a patent describing protease inhibitors invented by its scientists. Enanta has now followed that up with another filing in Europe, making the same accusation. Since being emergency authorised in 2021, anti-viral Paxlovid has generated Pfizer more than $26bn in global revenue. This includes a staggering $18.9bn in 2022 when Covid-19 cases were still prevalent. Despite waning demand for Covid-19 treatments, the pill still brought in $1.2bn in 2024, buoyed by government orders. However, Enanta – known for co-developing hepatitis C virus treatment glecaprevir/pibrentasvir with AbbVie – believes Pfizer designed Paxlovid via unlawful means. The US biotech stated it is 'seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the '265 Patent) in the manufacture, use and sale of Pfizer's Covid-19 antiviral, Paxlovid'. In an emailed statement to Pharmaceutical Technology, a Pfizer spokesperson said: 'We are confident in our intellectual property (IP) surrounding Paxlovid and will respond in due course in court.' The lawsuit, filed in the European Union's (EU) Unified Patent Court (UPC), targets Pfizer's commercial activity in the 18 countries of the EU. The company confirmed the '265 patent in question is the European counterpart of US patent number 11,358,953 (the '953 Patent) that is the centre of the US lawsuit. Although it is technically ongoing, Enanta's US lawsuit hit a major roadblock. In December 2024, a federal judge in Massachusetts sided with Pfizer, granting that the '953 patent is invalid. Enanta confirmed at the time it would appeal the decision, adding it 'believes strongly in the merits of our case'. Pfizer reported strong Q2 2025 results this month, bucking a tepid earnings window that gripped the wider pharma industry. Sales for the Paxlovid grew 71% while the Covid-19 vaccine Comirnaty revenue surged 95%. However, the legal challenge posed by Enanta marks the second issue Pfizer has had to firefight this week. The big pharma company reported a Phase III trial failure for a sickle cell disease candidate purchased as part of a $5.4bn takeover of Global Blood Therapeutics in 2022. "Pfizer battles another Paxlovid lawsuit from Enanta" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Wall Street Journal
3 hours ago
- Wall Street Journal
‘What Doesn't Kill Us' Review: Freeze Your Enthusiasm
In 2017 the investigative journalist Scott Carney wrote 'What Doesn't Kill Us.' The book featured Wim Hof, an unorthodox health trainer from Holland who could push people (including Mr. Carney) past previously unthinkable physical barriers. The book became a bestseller and helped transform Mr. Hof into a celebrity, popularizing his training methods—particularly cold plunges, which involve immersing oneself in frigid water for a few minutes at a time. Capitalizing on the sales of 'What Doesn't Kill Us,' in 2020 Mr. Hof wrote his own book, which has been translated into multiple languages. Never mind that Mr. Carney's book came with an ominous full-page disclaimer, warning that the practices described in the book 'are inherently dangerous and could result in grave harm or death.' It's tempting to dismiss the foreboding tone as a publicity stunt to juice sales. But since then, Mr. Carney tells us in a new edition of his book, he has 'collected more than thirty reports of people who have drowned while following Hof's example by practicing his breathwork techniques in water.' In a 15-page afterword to the new edition, Mr. Carney tells us that Mr. Hof's representatives respond by insisting there are warnings—for instance, in the descriptions attached to Mr. Hof's demonstration videos on YouTube—against using his breathing techniques 'in a swimming pool, before going underwater, beneath the shower, or piloting any vehicle.' Mr. Carney isn't convinced, citing a video marketed by Mr. Hof in which he contradicts his own guidance. 'At the very least, the juxtaposition between the written warning and Hof's own words is confusing. At worst, it's a dramatic acknowledgment of the sort of negligence that could get someone killed.'
